Rein Therapeutics, Inc. (RNTX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.59

From 52W high−70.64%

Volume502153.00

Market cap$47.62M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$0.59

From 52W high

−70.64%

Volume

502153.00

Market cap

$47.62M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

P/E (TTM)

—

RSI (14)

31.2

MomentumView details →

1D Return

−6.49%

YTD Return

−51.72%

SummaryUpdated Jun 1, 2026

Rein Therapeutics Inc. (NASDAQ:RNTX) is a clinical-stage biopharmaceutical company founded in 2001 by a team of scientists including Gregory L. Verdine, Rosana Kapeller, and Loren David Walensky. Based in Austin, Texas, the company went public in June 2017 and focuses on developing novel therapeutic approaches for treating cancer and other diseases. Rein Therapeutics represents the growing field of precision oncology, where treatments are designed to target specific molecular pathways involved in cancer development and progression.

Ask drillr about Rein Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

4.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−487.90%

ROA (TTM)

−75.43%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+31.72%

FCF YoY

+11.27%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+44.16%

EBITDA YoY

+65.33%

MomentumView details →

1D Return

−6.49%

YTD Return

−51.72%

1Y Return

−56.25%

RSI (14)

31.2

vs 50D SMA

−27.74%

vs 200D SMA

−47.35%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

4.27x

Quick Ratio

4.27x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.10

EPS Surprise

41.18%

Beats (12Q)

4/12

Next Q EPS Est

−$0.13

Avg Surprise (4Q)

−73.36%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−49.76M

Op. CF (TTM)

−18.83M

Next earningsNov 13, 2026 →

Latest newsMore news →

Rein Therapeutics reported its financial results for the second quarter ended June 30, 2026.67d ago

Rein Therapeutics announced publication of first-in-human clinical data for LTI-03 in Nature Communications, supporting its ongoing Phase 2 RENEW trial for idiopathic pulmonary fibrosis.76d ago

Similar companies

New Ray Medicine International Holding Ltd.06108.HK ETHZilla CorporationFRMM Universal Health International Group Holding Limited02211.HK China Healthwise Holdings Limited00348.HK Atlantic International CorpCIRC LifeMD, Inc.LFMDP Find similar companies →

Latest newsMore news →

Rein Therapeutics reported its financial results for the second quarter ended June 30, 2026.67d ago Rein Therapeutics announced publication of first-in-human clinical data for LTI-03 in Nature Communications, supporting its ongoing Phase 2 RENEW trial for idiopathic pulmonary fibrosis.76d ago Rein Therapeutics announced that its Phase 2 RENEW clinical trial is now open and enrolling patients across all five planned countries.90d ago